Search

Your search keyword '"Juodzbaliene E"' showing total 3 results
Start Over Author "Juodzbaliene E"
3 results on '"Juodzbaliene E"'

1. Leiomyosarcoma of the inferior vena cava

Author

Krasauskas, Kavaliauskiene G, Lukosevicius S, Pranys D, Mitraite D, Jonaitiene E, Algidas Basevičius, Bieliūniene E, and Juodzbaliene E

Subjects
Leiomyosarcoma, medicine.medical_specialty, surgical treatment, Radiography, radiological and pathological examination, 030204 cardiovascular system & hematology, Inferior vena cava, leiomyosarcoma, inferior vena cava, 03 medical and health sciences, 0302 clinical medicine, Blood vessel prosthesis, Biopsy, Medicine, cardiovascular diseases, Surgical treatment, medicine.diagnostic_test, business.industry, Magnetic resonance imaging, General Medicine, medicine.disease, 3. Good health, body regions, medicine.vein, 030220 oncology & carcinogenesis, cardiovascular system, Radiology, Ultrasonography, business
Abstract

Leiomyosarcoma is a rare tumor of mesenchymal origin usually affecting the inferior vena cava. Early diagnosis is essential before surgical resection, which is the only therapeutic modality that prolongs patients’ survival. Ultrasonography, computer tomography, and magnetic resonance imaging are the main imaging modalities in this case. Combined with guided biopsies, they form the mainstay of reliable diagnosis. We report a case with retroperitoneal tumor arising from the middle segment of the inferior vena cava. Radiological examination revealed retroperitoneal tumor and helped to choose surgical treatment. Histopathological examination confirmed the diagnosis of leiomyosarcoma of the inferior vena cava.

Published
2010

2. Leiomyosarcoma of the inferior vena cava.

Author

Bieliūniene E, Kavaliauskiene G, Mitraite D, Jonaitiene E, Basevicius A, Lukosevicius S, Pranys D, Krasauskas V, and Juodzbaliene E

Subjects
Biopsy, Blood Vessel Prosthesis, Female, Follow-Up Studies, Humans, Liver pathology, Liver Neoplasms diagnostic imaging, Liver Neoplasms pathology, Liver Neoplasms secondary, Magnetic Resonance Imaging, Radiography, Abdominal, Time Factors, Tomography, X-Ray Computed, Ultrasonography, Doppler, Color, Vena Cava, Inferior pathology, Leiomyosarcoma diagnosis, Leiomyosarcoma diagnostic imaging, Leiomyosarcoma pathology, Leiomyosarcoma surgery, Retroperitoneal Neoplasms diagnosis, Retroperitoneal Neoplasms diagnostic imaging, Retroperitoneal Neoplasms pathology, Retroperitoneal Neoplasms surgery, Vascular Neoplasms diagnosis, Vascular Neoplasms diagnostic imaging, Vascular Neoplasms pathology, Vascular Neoplasms surgery
Abstract

Leiomyosarcoma is a rare tumor of mesenchymal origin usually affecting the inferior vena cava. Early diagnosis is essential before surgical resection, which is the only therapeutic modality that prolongs patients' survival. Ultrasonography, computer tomography, and magnetic resonance imaging are the main imaging modalities in this case. Combined with guided biopsies, they form the mainstay of reliable diagnosis. We report a case with retroperitoneal tumor arising from the middle segment of the inferior vena cava. Radiological examination revealed retroperitoneal tumor and helped to choose surgical treatment. Histopathological examination confirmed the diagnosis of leiomyosarcoma of the inferior vena cava.

Published
2010

3. [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].

Author

Liutkauskiene S, Sveikata A, Juozaityte E, Characiejus D, Juodzbaliene E, Kregzdyte R, and Fokas V

Subjects
Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Agents administration & dosage, Docetaxel, Doxorubicin administration & dosage, Female, Humans, Informed Consent, Middle Aged, Neutropenia chemically induced, Quality of Life, Recombinant Proteins, Taxoids administration & dosage, Time Factors, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Doxorubicin therapeutic use, Granulocyte Colony-Stimulating Factor therapeutic use, Neutropenia prevention & control, Taxoids therapeutic use
Abstract

Background: We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer., Patients and Methods: Three centers in Lithuania enrolled 36 patients who received rGCSF (5 microg/kg/d) on day 2 of each 21-day chemotherapy with docetaxel 75 mg/m(2) and doxorubicin 50 mg/m(2) (AT) starting in the first cycle. Treatment regimen was repeated for up to six cycles., Results: Leukocytosis, bone pain, and headache were the most frequent adverse events, with incidence rates of 22%, 19%, and 8%, respectively. Adverse events were typical for rGCSF in this patient population. Overall incidence rate of febrile neutropenia was 14%. The mean duration of febrile neutropenia episodes across cycles was 2.14 days. Incidence of chemotherapy delay was 2%. There was no reduction in chemotherapy dose due to expected toxicity or side effects. Intravenous antibiotics for the treatment of febrile neutropenia were needed in 19% of cases. Quality-of-life assessment shows a significant improvement in emotional functioning and a significant decrease in pain score. The efficacy profile of rGCSF observed in the present study was comparable with that of other rGCSF products previously described in the published scientific literature., Conclusions: The primary prophylaxis of neutropenia and its complications by rGCSF was safe and effective for women with metastatic breast cancer who received chemotherapy with docetaxel and doxorubicin.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results